- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment PSP is a degenerative disease that, like Parkinson's disease, causes symptoms such ...

On October 13, GemVax & KAEL announced that it held a plaque unveiling ceremony for the "International Progressive ...

After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...

GemVax & Kael announced on the 6th that it will establish the 'International Progressive Supranuclear Palsy (PSP) Treatment Center' together with Bundang Seoul National University Hospital and CurePSP ...

Progressive supranuclear palsy (PSP) is a rare, degenerative neurological condition. It usually starts in middle age and can cause symptoms similar to those of Parkinson’s disease. PSP can cause ...

The International PSP Research and Treatment Center (the "Center") will integrate the infrastructure and expertise of the three parties to execute a comprehensive array of functions, including ...